Introduction
Among the various procedures proposed for use in assessing the mutagenic potential of drugs, the dominant-lethal (D-L) assay stands currently as one of the few tests for measuring mutagenic effects on germ cells. Early identification of the D-L assay as a possible member of a test battery relates strongly to its being a mammalian model. Many scientists within the pharmaceutical industry believe that only those tests which utilize a mammalian model should be considered for primary use in drug safety evaluation protocols. The reason for such belief is obvious when one considers that the entire process of drug safety evaluation is oriented on established concepts in pharmacology and toxicology. Mammalian processes of assimilation, absorption, distribution, metabolism and elimination must be permitted to work on the chemical under test in order to provide some basis for extrapolating mutagenicity test data to man (1) . Dose levels tested in these models and routes of drug administration should both reflect human use. Also, differences in the qualitative pharmacologic action of drugs must be considered as an essential part of the criteria applied to dose selection. Test reproducibility and dose-effect relationships *Medical Research Laboratories, Pfizer Central Research, Groton, Connecticut 06340. must be emphasized in mutagenicity studies in order to identify those levels at which any mutagenic action is first detectable and to relate this level to the dose required for therapeutic efficacy.
In this presentation, data have been selected from a number of D-L studies which relate to these points and the difficulties encountered in interpreting D-L test results.
Methods
Random-bred CD-1 mice (Charles River), 8 weeks of age, were used in all experiments except where noted. Generally, 15 males were assigned to each test and control group, and 2 females were caged with each male. Pregnant females were identified by the presence of a mating plug. The number of total and dead implants/pregnant female were determined by autopsy at 12-14 days of pregnancy. Statistical analyses were computerized and all tests of significance were performed on arcsine transformed data. Weekly summations of test data were compared to a control regression computed across the entire 8 weeks of testing (2) . These statistical models are discussed in the paper by Dr. David Salsburg (3).
Results and Discussion

Strain Characterization
Continuous surveillance of the mouse December 1973 Occasionally, a genetically aberrant male is encountered which produces a D-L effect in several stages of spermatogenesis. weeks. A dose-response curve is shown in Figure 1 for the period 7-11 days following mating (5) . Another example of a reproducible D-L effect is depicted in Table 5 . The purine analog, 6-mercaptopurine has produced a consistent D-L effect during weeks 5 and 6 of the spermatogenic cycle (6) . Again, the parameter of living implants/pregnant female showed a simultaneous and significant reduction.
Nonreproducible Results
In contrast to the reproducibility obtainedl Tables 7-12 show the kind of inconsistenkind of results is shown in Table 6 . The com-cies which may occur in the dominant-lethal pound produced effects on two separate assay with a nonmutagenic substance. The stages of spermatogenesis in the first two response at week 7 at a dose of 7.5 mg/kg experiments. A third experiment performed (Table 8 ) was not reproduced at a level of 75 at the same dose level was negative in both mg/kg (Table 10) . Further, the response C  T  C  T  C  T  C  T  C  T  C  T  1  26  33  319  2  43  38  535  3  39  43  460  4  34  52  435  5  41  34  498  6  28  24  360  7  44  28  563  8  48  37 December 1973 during week 3 at the dose level of 75 mg/kg is performed on a weekly basis and the parawas not reproduced at 150 mg/kg (Table 12) . meters of total and living implants are exIt should be noted that here again, no signifiamined simultaneously with dead implants/ cant reduction was observed in either the topregnant female. In addition, this compound tal or living implants/pregnant female at any was not active in any test for mutagenic podose level during the test. The investigator is tential including the host-mediated and in thus not mislead when the statistical analysis vivo cytogenetic assays. 
Effect of Dose Level
The qualitative pharmacologic action of drugs must be considered when choosing dose levels for D-L experiments. Drugs such as anesthetics and tranquillizers have such pronounced pharmacologic activity that excessive dose levels can produce marked temperature reductions and an inability to mate for several days following a single administration. An example of this kind of overdosage is shown in Figure 2 
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observed at levels which were tested for mutagenic activity (7, 8) . Clearly, such reductions must reduce the overall metabolism of the test animal and therefore influence the metabolism of the drug. Levels of drug used in mutagenicity assessments should be chosen so as not to produce anorexia, sedation, or other exaggerated pharmacological effects (9) .
Conclusions
In interpreting D-L data, the need for demonstrating a statistically significant and reproducible effect in the same stage of spermatogenesis cannot be over emphasized. In order to achieve consistent analyses, the degree of variability in important parameters of dead, living and total implants per pregnant female has to be firmly established for each strain 
